[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635347":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":36,"locations":42,"responsibleParty":68,"collaborators":11,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":11,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":11,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Bisirna Therapeutics (Suzhou) Co., Ltd.","INDUSTRY",[8,15,18,21,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort1","EXPERIMENTAL",null,[13,14],"Drug: BSA204","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Cohort3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Cohort4",[13,14],{"label":25,"type":10,"description":11,"interventionNames":26},"Cohort5",[13,14],[28,33],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","BSA204","BSA204 Injection",[9,16,19,22,25],{"type":29,"name":34,"description":34,"armGroupLabels":35,"otherNames":11},"Placebo",[9,16,19,22,25],[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Charlene Si","CONTACT","13816432852","charlene.si@bisirna.com",[43,60],{"facility":44,"status":11,"city":45,"state":46,"zip":11,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Peking University First Hospital","Beijing","Beijing Municipality","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56],{"name":57,"role":39,"phone":58,"phoneExt":11,"email":59},"Jianping Li","010-66110802","lijianping03455@pkufh.com",{"facility":44,"status":11,"city":45,"state":46,"zip":11,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},{"type":50,"coordinates":62},[52,53],{"lat":53,"lon":52},[65],{"name":66,"role":39,"phone":58,"phoneExt":11,"email":67},"Xia Zhao","xyjk@126.com",{"type":69,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100635347","phase-1-safety-pk-and-pd-of-bsa204-in-chinese-adults-with-borderline-elevated-lipoproteina-100635347",false,"NCT07551505","Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of BSA204 Injection in Chinese Adults With Borderline Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Body mass index (BMI) 18 to 30 kg\u002Fm2\n* Fasting triglycerides (TG) ≤ 4.5 mmol\u002FL\n* Borderline elevated fasting lipoprotein(a) \\[Lp(a)\\] levels as defined in the protocol\n* Fasting low-density lipoprotein cholesterol (LDL-C) within the range specified for the assigned dose cohort\n* o clinically significant abnormalities of hepatic or renal function\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* History or presence of significant medical conditions\n* Abnormal ECG findings, including a prolonged QTcF interval (\\> 450 msec for males or \\> 470 msec for females)\n* Prior treatment with small interfering RNA (siRNA) or antisense oligonucleotides within 12 months, or recent use of specific lipid-lowering therapies\n* Known allergy to any component of the study drug",true,"ALL","18 Years","55 Years",{"count":82,"type":83},40,"ESTIMATED","INTERVENTIONAL",[86],"PHASE1","The purpose of this Phase 1 clinical study is to evaluate the safety and tolerability of a single dose of BSA204 injection in Chinese adults with borderline high levels of lipoprotein(a) \\[Lp(a)\\].",[89],"Dyslipidemias","NOT_YET_RECRUITING","2026-04-23",{"date":93,"type":94},"2026-04-28","ACTUAL",{"date":96,"type":83},"2026-04-20",{"date":98,"type":83},"2027-12-31",{"name":5,"class":6},2]